Your session is about to expire
← Back to Search
Metarrestin for Advanced Cancer
Study Summary
This trial is studying a drug called metarrestin as a possible treatment for metastatic cancer.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had cancer other than the one currently being treated.I haven't had cancer treatment recently.I was diagnosed with cardiomyopathy less than 6 months ago.I have been diagnosed with pancreatic, colorectal, or breast cancer.I have a history of seizures or am at high risk for seizures.I am mostly able to care for myself and carry on normal activities.My cancer is growing quickly.My blood clotting levels are within a safe range.My liver tests are within the required range.My kidney function, measured by creatinine levels or eGFR, is within the required range.I agree to use birth control during the study.I weigh more than 35 kg.I am willing to have a biopsy and my cancer can be easily biopsied.I can swallow pills.I am HIV, HCV, or HBV positive and taking antiviral medication.I have brain metastases or brain disorders.I do not have any serious infections, including tuberculosis.I have recovered from previous treatment side effects to a mild level.I do not have any uncontrolled illnesses or conditions.My cancer cannot be surgically removed, has spread, and didn't respond to chemotherapy.I have had gastric bypass, use feeding tubes, or have conditions affecting nutrient absorption.I am a teenager with cancer, but it's not rhabdomyosarcoma.I am an adult with a confirmed solid tumor diagnosis.
- Group 1: 1/Arm 1
- Group 2: 2/Arm 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people have taken part in this clinical research thus far?
"Affirmative. Per clinicaltrials.gov, this trial is presently recruiting patients for its study which was first posted on October 27th 2020 and subsequently revised on October 21st 2022. This medical research project necessitates the recruitment of 64 individuals from 2 locations."
What adverse effects might arise from taking Metarrestin?
"Due to the primitive stage of research, we have assigned Metarrestin a safety rating of 1 on our scale. This Phase 1 trial indicates only limited data supporting its efficacy and safety."
Are there any vacancies left to take part in this experiment?
"According to clinicaltrials.gov, this active trial was initiated on October 27th 2020 and its status was recently updated on October 21st 2022."
What objectives is this clinical trial striving to accomplish?
"This clinical trial is designed to gauge the maximum tolerated dose (MTD) of metarrestin in subjects with metastatic solid tumors, which will be measured over a bi-monthly period. Secondary objectives include assessing safety and tolerability as well as calculating Objective Response Rate (ORR), Duration of Overall Response (DOR) rate via Kaplan-Meier curves for RECIST 1.1 criteria."
Share this study with friends
Copy Link
Messenger